Back

New dimensions in cardiovascular risk: exploring the latest cardiovascular outcomes trials in type 2 diabetes

3 September 2019 (16:00 - 16:05)
Organised by:
Congress Presentation Part of: Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk Diabetes and the Heart ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

3 More presentations in this session

Presentation thumbnail
Analysing the advantages of glucagon-like peptide-1 receptor agonists/sodium-glucose cotransporter 2 inhibitors in high vs. low cardiovascular disease risk
Professor J. Deanfield (London, GB)
Slides Video
Presentation thumbnail
Exploring the future role of glucagon-like peptide-1 receptor agonists in cardiovascular disease risk reduction
Doctor B. Scirica (Boston, US)
Slides Video
Presentation thumbnail
Connecting with the speakers: Questions and Answers
Doctor M. Kosiborod (Kansas City, US) Professor J. Deanfield (London, GB) Doctor B. Scirica (Boston, US)
Slides Video

Access the full session

Session thumbnail
Experts on the spot: exploring new dimensions in glucagon-like peptide-1 receptor agonists and cardiovascular risk

The Event

Event poster

ESC Congress 2019

3 September 2019 16:00 CET
You may be interested in
thumbnail
Webinar
Prevention of heart failure in diabetic patients at population level
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources